Reviewer's report

**Title:** Expression of Follicle-Stimulating Hormone receptor by the vascular endothelium in tumor metastases

**Version:** 3  **Date:** 30 January 2013

**Reviewer:** Luigi Tornillo

**Reviewer's report:**

Siraj et al. describe the expression of the Follicle Stimulating Hormone receptor (FSHR) in the vasculature of metastasis from different primaries (lung, breast, prostate, colon, and kidney) to different sites (liver, lymph node, bone, pleura, and brain). On the basis of their previous results, they have hypothesized that the expression could be specific of the metastasis. They have performed a pure immunohistochemical study on the tissues of 203 patients. The primary antibody was produced as previously described (Vannier et al., Biochemistry, 1996). The staining was found only in the vessel of metastases, but not in the control tissues. There was significant difference between the density of FSHR-positive vessels in the exterior of prostate metastases in comparison with the interior. No difference was found for other primaries. Also, regarding the metastatic site, prostate cancer metastases in the brain were richer in FSHR-positive vessels as metastases in the lymph nodes. Apart from estrogen receptor in breast cancer metastases, no significant relationship was found with clinicopathological parameters. No positivity was found in nontumoral tissue. The authors claim that FSHR could be used as imaging target and/or as therapeutic target.

The paper is very interesting and new and in my opinion it should be published, in the present form.

**Level of interest:** An article of outstanding merit and interest in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests